Castle Biosciences (CSTL) EPS (Weighted Average and Diluted) (2018 - 2026)

Castle Biosciences has disclosed EPS (Weighted Average and Diluted) across 9 years of filings, most recently posting -$0.49 for Q1 2026.

• EPS (Weighted Average and Diluted) for Q1 2026 came in at -$0.49, up 45.56% year-over-year; the trailing twelve-month figure through Mar 2026 was -$0.43 (down 126.32% YoY), and the FY2025 annual result was -$0.83, down 233.87% from the prior year.
• EPS (Weighted Average and Diluted) came in at -$0.49 for Q1 2026 at Castle Biosciences, down from -$0.07 in the prior quarter.
• In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $0.32 in Q4 2024 to a low of -$1.1 in Q1 2023.
• The 5-year median for EPS (Weighted Average and Diluted) is -$0.09 (2023), against an average of -$0.32.
• Across the five-year window, EPS (Weighted Average and Diluted) sank 1066.67% in 2023 and soared 455.56% in 2024, its largest moves.
• Castle Biosciences' EPS (Weighted Average and Diluted) stood at -$0.79 in 2022, then soared by 88.61% to -$0.09 in 2023, then soared by 455.56% to $0.32 in 2024, then slumped by 121.87% to -$0.07 in 2025, then slumped by 600.0% to -$0.49 in 2026.
• The last three EPS (Weighted Average and Diluted) figures came in at -$0.49 (Q1 2026), -$0.07 (Q4 2025), and -$0.02 (Q3 2025), per Business Quant data.